{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T17:52:28Z","timestamp":1784310748741,"version":"3.55.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014042","name":"US Department of Defense Peer Reviewed Cancer Research Program","doi-asserted-by":"publisher","award":["CA190276"],"award-info":[{"award-number":["CA190276"]}],"id":[{"id":"10.13039\/100014042","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["P30-CA077598"],"award-info":[{"award-number":["P30-CA077598"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["T32-CA009138"],"award-info":[{"award-number":["T32-CA009138"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"National Institutes of Health Office of the Director","doi-asserted-by":"publisher","award":["T35-OD011118"],"award-info":[{"award-number":["T35-OD011118"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000052","name":"National Institutes of Health Office of the Director","doi-asserted-by":"publisher","award":["K01-OD031810"],"award-info":[{"award-number":["K01-OD031810"]}],"id":[{"id":"10.13039\/100000052","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011539","name":"University of Minnesota Masonic Cancer Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100032516","name":"Medical School, University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100032516","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000885","name":"Children's Cancer Research Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000885","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007249","name":"University of Minnesota","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007249","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001250","name":"Morris Animal Foundation","doi-asserted-by":"publisher","award":["D18CA-050"],"award-info":[{"award-number":["D18CA-050"]}],"id":[{"id":"10.13039\/100001250","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.jpet.2025.103674","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T20:58:14Z","timestamp":1755550694000},"page":"103674","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Remodeling the sarcoma microenvironment by simultaneous targeting of urokinase-type plasminogen activator receptors and epidermal growth factor receptors to promote antitumor activity"],"prefix":"10.1016","volume":"392","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-3114-7844","authenticated-orcid":false,"given":"Ashley J.","family":"Schulte","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9026-9883","authenticated-orcid":false,"given":"Mitzi","family":"Lewellen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9463-9689","authenticated-orcid":false,"given":"Willa","family":"Durose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4396-0856","authenticated-orcid":false,"given":"Erin","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6985-8070","authenticated-orcid":false,"given":"Leyla","family":"Taghizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Todhunter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-1409-787X","authenticated-orcid":false,"given":"Courtney","family":"Bush","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haeree P.","family":"Lang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2740-9119","authenticated-orcid":false,"given":"Mary E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5235-753X","authenticated-orcid":false,"given":"Taylor A.","family":"DePauw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7878-2370","authenticated-orcid":false,"given":"Kelly M.","family":"Makielski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1645-0036","authenticated-orcid":false,"given":"Jong Hyuk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren E.","family":"Burt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Overn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5593-882X","authenticated-orcid":false,"given":"Colleen L.","family":"Forster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davis M.","family":"Seelig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5463-1153","authenticated-orcid":false,"given":"M. Gerard","family":"O\u2019Sullivan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1080-1402","authenticated-orcid":false,"given":"Brenda J.","family":"Weigel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paari","family":"Murugan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8455-980X","authenticated-orcid":false,"given":"Gary R.","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Troy C.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Vallera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6398-7648","authenticated-orcid":false,"given":"Jaime F.","family":"Modiano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpet.2025.103674_bib1","series-title":"Sarcomas","first-page":"13","article-title":"Surgical oncology","author":"Fairweather","year":"2020"},{"key":"10.1016\/j.jpet.2025.103674_bib2","series-title":"Sarcomas","first-page":"3","article-title":"Medical oncology","author":"Ratan","year":"2020"},{"issue":"4","key":"10.1016\/j.jpet.2025.103674_bib3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrclinonc.2014.26","article-title":"Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies","volume":"11","author":"Linch","year":"2014","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103674_bib4","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1200\/JCO.2017.75.1610","article-title":"Emerging targeted and immune-based therapies in sarcoma","volume":"36","author":"Pollack","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103674_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001580","article-title":"Immunotherapy for sarcomas: new frontiers and unveiled opportunities","volume":"9","author":"Birdi","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.jpet.2025.103674_bib6","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/S1470-2045(17)30624-1","article-title":"Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial","volume":"18","author":"Tawbi","year":"2017","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103674_bib7","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1158\/1535-7163.MCT-16-0637","article-title":"Safe and effective sarcoma therapy through bispecific targeting of EGFR and uPAR","volume":"16","author":"Borgatti","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.jpet.2025.103674_bib8","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/his.14443","article-title":"Mesenchymal neoplasms with NTRK and other kinase gene alterations","volume":"80","author":"Davis","year":"2022","journal-title":"Histopathology"},{"issue":"3","key":"10.1016\/j.jpet.2025.103674_bib9","doi-asserted-by":"crossref","first-page":"557","DOI":"10.3390\/cancers13030557","article-title":"Candidate biomarkers for specific intraoperative near-infrared imaging of soft tissue sarcomas: a systematic review","volume":"13","author":"Rijs","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"10","key":"10.1016\/j.jpet.2025.103674_bib10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.3109\/07357907.2014.964409","article-title":"ErbB receptors as prognostic and therapeutic drug targets in bone and soft tissue sarcomas","volume":"32","author":"Wang","year":"2014","journal-title":"Cancer Invest"},{"issue":"9","key":"10.1016\/j.jpet.2025.103674_bib11","first-page":"1017","article-title":"Altered expression of urokinase-type plasminogen activator and plasminogen activator inhibitor in high-risk soft tissue sarcomas","volume":"22","author":"Benassi","year":"2007","journal-title":"Histol Histopathol"},{"key":"10.1016\/j.jpet.2025.103674_bib12","first-page":"113","article-title":"Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin","volume":"10","author":"Oh","year":"2018","journal-title":"Clin Pharmacol"},{"issue":"15","key":"10.1016\/j.jpet.2025.103674_bib13","doi-asserted-by":"crossref","first-page":"11938","DOI":"10.18632\/oncotarget.21187","article-title":"Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors","volume":"9","author":"Pilbeam","year":"2018","journal-title":"Oncotarget"},{"issue":"19","key":"10.1016\/j.jpet.2025.103674_bib14","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2174\/138161211796718152","article-title":"Development of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinic","volume":"17","author":"Mazar","year":"2011","journal-title":"Curr Pharm Des"},{"issue":"6","key":"10.1016\/j.jpet.2025.103674_bib15","doi-asserted-by":"crossref","first-page":"956","DOI":"10.3390\/biom10060956","article-title":"Bispecific targeting of EGFR and urokinase receptor (uPAR) using ligand-targeted toxins in solid tumors","volume":"10","author":"Oh","year":"2020","journal-title":"Biomolecules"},{"issue":"5","key":"10.1016\/j.jpet.2025.103674_bib16","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1158\/1541-7786.MCR-20-0937","article-title":"Genomically complex human angiosarcoma and canine hemangiosarcoma establish convergent angiogenic transcriptional programs driven by novel gene fusions","volume":"19","author":"Kim","year":"2021","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.jpet.2025.103674_bib17","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/1471-2407-14-269","article-title":"Expression of uPAR in tumor-associated stromal cells is associated with colorectal cancer patient prognosis: a TMA study","volume":"14","author":"Boonstra","year":"2014","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jpet.2025.103674_bib18","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/jlb.66.1.40","article-title":"Urokinase plasminogen activator receptor (CD87) expression of tumor-associated macrophages in ductal carcinoma in situ, breast cancer, and resident macrophages of normal breast tissue","volume":"66","author":"Hildenbrand","year":"1999","journal-title":"J Leukoc Biol"},{"issue":"8","key":"10.1016\/j.jpet.2025.103674_bib19","first-page":"1911","article-title":"Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma","volume":"53","author":"Pyke","year":"1993","journal-title":"Cancer Res"},{"issue":"6","key":"10.1016\/j.jpet.2025.103674_bib20","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1158\/2767-9764.CRC-23-0441","article-title":"Hemangiosarcoma cells promote conserved host-derived hematopoietic expansion","volume":"4","author":"Kim","year":"2024","journal-title":"Cancer Res Commun"},{"issue":"2","key":"10.1016\/j.jpet.2025.103674_bib21","first-page":"275","article-title":"Mutatect: a mouse tumour model for detecting radiation-induced mutations in vivo","volume":"430","author":"Birnboim","year":"1999","journal-title":"Mutat Res"},{"issue":"8","key":"10.1016\/j.jpet.2025.103674_bib22","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1002\/ijc.28187","article-title":"Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors","volume":"133","author":"Schappa","year":"2013","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.jpet.2025.103674_bib23","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s11060-010-0392-5","article-title":"A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature","volume":"103","author":"Tsai","year":"2011","journal-title":"J Neurooncol"},{"issue":"1","key":"10.1016\/j.jpet.2025.103674_bib24","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s002620050460","article-title":"Modification of ricin A chain, by addition of endoplasmic reticulum (KDEL) or Golgi (YQRL) retention sequences, enhances its cytotoxicity and translocation","volume":"46","author":"Zhan","year":"1998","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.jpet.2025.103674_bib25","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.3171\/2010.11.JNS101214","article-title":"Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain","volume":"114","author":"Oh","year":"2011","journal-title":"J Neurosurg"},{"issue":"12","key":"10.1016\/j.jpet.2025.103674_bib26","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1016\/j.oraloncology.2012.06.002","article-title":"Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma","volume":"48","author":"Waldron","year":"2012","journal-title":"Oral Oncol"},{"key":"10.1016\/j.jpet.2025.103674_bib27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.3389\/fphar.2015.00154","article-title":"Urokinase receptor and resistance to targeted anticancer agents","volume":"6","author":"Gonias","year":"2015","journal-title":"Front Pharmacol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103674_bib28","doi-asserted-by":"crossref","first-page":"207","DOI":"10.18632\/oncoscience.146","article-title":"HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer","volume":"2","author":"Indira Chandran","year":"2015","journal-title":"Oncoscience"},{"issue":"10","key":"10.1016\/j.jpet.2025.103674_bib29","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1038\/s41416-020-01033-x","article-title":"Pre-clinical animal models are poor predictors of human toxicities in phase 1 oncology clinical trials","volume":"123","author":"Atkins","year":"2020","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.jpet.2025.103674_bib30","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40139-015-0086-y","article-title":"Mouse models as predictors of human responses: evolutionary medicine","volume":"3","author":"Uhl","year":"2015","journal-title":"Curr Pathobiol Rep"},{"issue":"9","key":"10.1016\/j.jpet.2025.103674_bib31","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1038\/nbt0906-1065b","article-title":"The dog as a cancer model","volume":"24","author":"Khanna","year":"2006","journal-title":"Nat Biotechnol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103674_bib32","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/nrc2273","article-title":"Translation of new cancer treatments from pet dogs to humans","volume":"8","author":"Paoloni","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jpet.2025.103674_bib33","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s40425-016-0200-7","article-title":"Canine cancer immunotherapy studies: linking mouse and human","volume":"4","author":"Park","year":"2016","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.jpet.2025.103674_bib34","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/s41568-020-0297-3","article-title":"Improving human cancer therapy through the evaluation of pet dogs","volume":"20","author":"LeBlanc","year":"2020","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10.1016\/j.jpet.2025.103674_bib35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1177\/030098589803500202","article-title":"Functional loss of p21\/Waf-1 in a case of benign canine multicentric melanoma","volume":"35","author":"Ritt","year":"1998","journal-title":"Vet Pathol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103674_bib36","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1016\/j.bone.2011.05.008","article-title":"Molecular subtypes of osteosarcoma identified by reducing tumor heterogeneity through an interspecies comparative approach","volume":"49","author":"Scott","year":"2011","journal-title":"Bone"},{"issue":"1","key":"10.1016\/j.jpet.2025.103674_bib37","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.yexcr.2014.02.020","article-title":"Interleukin-8 promotes canine hemangiosarcoma growth by regulating the tumor microenvironment","volume":"323","author":"Kim","year":"2014","journal-title":"Exp Cell Res"},{"issue":"2","key":"10.1016\/j.jpet.2025.103674_bib38","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/jcb.240450211","article-title":"Progesterone augments proliferation induced by epidermal growth factor in a feline mammary adenocarcinoma cell line","volume":"45","author":"Modiano","year":"1991","journal-title":"J Cell Biochem"},{"issue":"9","key":"10.1016\/j.jpet.2025.103674_bib39","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3390\/toxins16090376","article-title":"Toxicity profile of eBAT, a bispecific ligand-targeted toxin directed to EGFR and uPAR, in mice and a clinical dog model","volume":"16","author":"Dicovitsky","year":"2024","journal-title":"Toxins (Basel)"},{"issue":"11","key":"10.1016\/j.jpet.2025.103674_bib40","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00262-015-1749-6","article-title":"Mesenchymal stromal cells inhibit murine syngeneic anti-tumor immune responses by attenuating inflammation and reorganizing the tumor microenvironment","volume":"64","author":"Modiano","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"2","key":"10.1016\/j.jpet.2025.103674_bib41","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1080\/00031305.2016.1154108","article-title":"The ASA statement on p-values: context, process, and purpose","volume":"70","author":"Wasserstein","year":"2016","journal-title":"Am Stat"},{"key":"10.1016\/j.jpet.2025.103674_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.663225","article-title":"CRISPR\/Cas9 uPAR gene knockout results in tumor growth inhibition, EGFR downregulation and induction of stemness markers in melanoma and colon carcinoma cell lines","volume":"11","author":"Biagioni","year":"2021","journal-title":"Front Oncol"},{"issue":"5","key":"10.1016\/j.jpet.2025.103674_bib43","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/sj.onc.1209833","article-title":"A direct link between expression of urokinase plasminogen activator receptor, growth rate and oncogenic transformation in mouse embryonic fibroblasts","volume":"26","author":"Mazzieri","year":"2007","journal-title":"Oncogene"},{"issue":"5","key":"10.1016\/j.jpet.2025.103674_bib44","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/00001813-200106000-00001","article-title":"The urokinase plasminogen activator receptor (uPAR) as a target for the diagnosis and therapy of cancer","volume":"12","author":"Mazar","year":"2001","journal-title":"Anticancer Drugs"},{"issue":"21","key":"10.1016\/j.jpet.2025.103674_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abn3774","article-title":"Therapeutic strategies targeting uPAR potentiate anti-PD-1 efficacy in diffuse-type gastric cancer","volume":"8","author":"Qin","year":"2022","journal-title":"Sci Adv"},{"issue":"21","key":"10.1016\/j.jpet.2025.103674_bib46","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.3390\/cancers13215376","article-title":"The urokinase receptor (uPAR) as a \u201cTrojan Horse\u201d in targeted cancer therapy: challenges and opportunities","volume":"13","author":"Metrangolo","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"7814","key":"10.1016\/j.jpet.2025.103674_bib47","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","article-title":"Senolytic CAR T cells reverse senescence-associated pathologies","volume":"583","author":"Amor","year":"2020","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.jpet.2025.103674_bib48","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1038\/nrm977","article-title":"uPAR: a versatile signalling orchestrator","volume":"3","author":"Blasi","year":"2002","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"28","key":"10.1016\/j.jpet.2025.103674_bib49","doi-asserted-by":"crossref","first-page":"16886","DOI":"10.1074\/jbc.270.28.16886","article-title":"The receptor for urokinase-type plasminogen activator is not essential for mouse development or fertility","volume":"270","author":"Bugge","year":"1995","journal-title":"J Biol Chem"},{"issue":"7","key":"10.1016\/j.jpet.2025.103674_bib50","doi-asserted-by":"crossref","first-page":"979","DOI":"10.3390\/biom10070979","article-title":"Mechanisms of resistance to immunotoxins containing Pseudomonas exotoxin A in cancer therapy","volume":"10","author":"Dieffenbach","year":"2020","journal-title":"Biomolecules"},{"issue":"4","key":"10.1016\/j.jpet.2025.103674_bib51","doi-asserted-by":"crossref","first-page":"165.e15","DOI":"10.1016\/j.urolonc.2014.12.001","article-title":"Urokinase-type plasminogen activator receptor (uPAR) expression is associated with T-stage and survival in urothelial carcinoma of the bladder","volume":"33","author":"Dohn","year":"2015","journal-title":"Urol Oncol"},{"issue":"2","key":"10.1016\/j.jpet.2025.103674_bib52","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1097\/01.ju.0000165150.46006.92","article-title":"Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis","volume":"174","author":"Ohba","year":"2005","journal-title":"J Urol"},{"issue":"3","key":"10.1016\/j.jpet.2025.103674_bib53","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10585-007-9136-0","article-title":"Tumoral and macrophage uPAR and MMP-9 contribute to the invasiveness of B16 murine melanoma cells","volume":"25","author":"Marconi","year":"2008","journal-title":"Clin Exp Metastasis"},{"issue":"1","key":"10.1016\/j.jpet.2025.103674_bib54","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1593\/neo.10728","article-title":"Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model","volume":"13","author":"Zhang","year":"2011","journal-title":"Neoplasia"},{"issue":"4","key":"10.1016\/j.jpet.2025.103674_bib55","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/gutjnl-2013-305933","article-title":"The urokinase plasminogen activator receptor (uPAR) controls macrophage phagocytosis in intestinal inflammation","volume":"64","author":"Genua","year":"2015","journal-title":"Gut"},{"issue":"7","key":"10.1016\/j.jpet.2025.103674_bib56","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/cdd.2008.58","article-title":"Innate apoptotic immunity: the calming touch of death","volume":"15","author":"Birge","year":"2008","journal-title":"Cell Death Differ"},{"issue":"1","key":"10.1016\/j.jpet.2025.103674_bib57","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13046-020-01786-6","article-title":"Progranulin induces immune escape in breast cancer via up-regulating PD-L1 expression on tumor-associated macrophages (TAMs) and promoting CD8+ T cell exclusion","volume":"40","author":"Fang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.jpet.2025.103674_bib58","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s43018-024-00775-4","article-title":"Tumor-associated macrophages restrict CD8+ T cell function through collagen deposition and metabolic reprogramming of the breast cancer microenvironment","volume":"5","author":"Tharp","year":"2024","journal-title":"Nat Cancer"},{"issue":"1","key":"10.1016\/j.jpet.2025.103674_bib59","doi-asserted-by":"crossref","first-page":"7661","DOI":"10.1038\/s41467-023-43548-w","article-title":"ID1 expressing macrophages support cancer cell stemness and limit CD8+ T cell infiltration in colorectal cancer","volume":"14","author":"Shang","year":"2023","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.jpet.2025.103674_bib60","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1186\/s12967-022-03675-2","article-title":"Single-cell transcriptomics reveals the role of macrophage-na\u00efve CD4+ T cell interaction in the immunosuppressive microenvironment of primary liver carcinoma","volume":"20","author":"Mo","year":"2022","journal-title":"J Transl Med"},{"issue":"9","key":"10.1016\/j.jpet.2025.103674_bib61","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/sj.cgt.7700625","article-title":"Enhancing antimelanoma immune responses through apoptosis","volume":"10","author":"Bianco","year":"2003","journal-title":"Cancer Gene Ther"},{"issue":"6","key":"10.1016\/j.jpet.2025.103674_bib62","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/j.1365-2893.2004.00541.x","article-title":"High levels of p53 protein expression do not correlate with p53 mutations in hepatocellular carcinoma","volume":"11","author":"Anzola","year":"2004","journal-title":"J Viral Hepat"},{"issue":"16","key":"10.1016\/j.jpet.2025.103674_bib63","doi-asserted-by":"crossref","first-page":"4150","DOI":"10.1016\/j.cell.2024.05.059","article-title":"Guidelines for minimal information on cellular senescence experimentation in vivo","volume":"187","author":"Ogrodnik","year":"2024","journal-title":"Cell"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398873?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356525398873?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:15:40Z","timestamp":1777943740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356525398873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":63,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0022356525398873"],"URL":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103674","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Remodeling the sarcoma microenvironment by simultaneous targeting of urokinase-type plasminogen activator receptors and epidermal growth factor receptors to promote antitumor activity","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jpet.2025.103674","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics.","name":"copyright","label":"Copyright"}],"article-number":"103674"}}